http://www.onclive.com/web-exclusives/Speculating-Spectrum-More-buzz-about-stock-prices-than-the-recently-approved-Fusilev-indication
"Another drug in the company’s pipeline, belinostat, is being tested in a pivotal phase II trial for patients with relapsed/refractory peripheral T-cell lymphoma. Enrollment has completed with data anticipated at American Society of Clinical Oncology (ASCO) annual meeting in June, possibly followed by a new drug application in late 2011 to early 2012."
http://chicago2011.asco.org/
Sendt fra ProInvestor gruppen
"Another drug in the company’s pipeline, belinostat, is being tested in a pivotal phase II trial for patients with relapsed/refractory peripheral T-cell lymphoma. Enrollment has completed with data anticipated at American Society of Clinical Oncology (ASCO) annual meeting in June, possibly followed by a new drug application in late 2011 to early 2012."
http://chicago2011.asco.org/
Sendt fra ProInvestor gruppen
